LOTUS EYE HOSP & INST L Latest Share Price (LOTUSEYE)
TODAY IN ONE LINE
LOTUSEYE rose 1.8% on light volume, outperforming Nifty's 0.3% move.
With a market cap of ₹234.27 Cr., it trades at a P/E of 2955.00. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
LOTUS EYE HOSP & INST L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.19x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 68.2% YoY
- ●Poor Capital ReturnsLow ROE of 0.1%
Latest LOTUS EYE HOSP & INST L News
What changed recently?
Recent events, corporate actions, and announcements.
LOTUS EYE HOSP & INST L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for LOTUS EYE HOSP & INST L, framed against the sector median so the premium or discount is obvious at a glance.
LOTUS EYE HOSP & INST L trades at a P/E of 2955.00× and P/B of 4.09×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
LOTUS EYE HOSP & INST L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for LOTUS EYE HOSP & INST L — derived from the latest tape, not yesterday's close.
LOTUS EYE HOSP & INST L last traded at ₹115.1 with an intraday range of ₹113–₹115.2 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹115.10| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 120.27 | +5.17 | +4.49% |
| R3 | 118.07 | +2.97 | +2.58% |
| R2 | 116.63 | +1.53 | +1.33% |
| R1 | 115.87 | +0.77 | +0.67% |
| PIVOT | 114.43 | -0.67 | -0.58% |
| CURRENT | 115.10 | — | — |
| S1 | 113.67 | -1.43 | -1.25% |
| S2 | 112.23 | -2.87 | -2.49% |
| S3 | 111.47 | -3.63 | -3.16% |
| S4 | 109.27 | -5.83 | -5.07% |
LOTUSEYE is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹113.12–₹113.12
Trading Inside opening range
LOTUS EYE HOSP & INST L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for LOTUS EYE HOSP & INST L — consolidated or standalone — with margins, YoY growth and key ratios inline.
LOTUS EYE HOSP & INST L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹234.27 Cr. and reported EPS of ₹0.30.
LOTUS EYE HOSP & INST L segment analysis : revenue and profit mix.
Disclosed business segments at LOTUS EYE HOSP & INST L with their share of revenue and profit, switchable between consolidated and standalone reporting.
LOTUS EYE HOSP & INST L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for LOTUS EYE HOSP & INST L.
Our AI distills the core fundamental drivers supporting LOTUS EYE HOSP & INST L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
LOTUS EYE HOSP & INST L's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Minimal leverage with debt-to-equity of 0.0019, fortress-like balance sheet strength.
Net profit margin of 14.97% TTM, competitive within specialty healthcare segment.
Niche specialty eye-care brand with advanced surgical capabilities and comprehensive services.
Positive operating cash flow of ₹0.51 Cr in latest quarter, solid earnings quality.
Book value per share of ₹31.41 quarterly, stable equity base supporting operations.
Key Risks.
Operating margin of 1.50% quarterly indicates profitability challenges versus peer benchmarks.
Extreme P/E valuation of 3,184.25x TTM, fundamentally unsustainable and speculative.
ROE of 0.13% and ROCE of 1.15% signal critically weak capital efficiency.
Latest quarterly EPS of ₹0.06 shows earnings volatility despite revenue growth.
Promoter holding fell from 58.17% to 40.03%, indicating significant shareholder dilution.
Flip Conditions.
Valuation risk. a P/E above 3842 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
LOTUS EYE HOSP & INST L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — LOTUS EYE HOSP & INST L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
LOTUS EYE HOSP & INST L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for LOTUS EYE HOSP & INST L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
LOTUS EYE HOSP & INST L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for LOTUS EYE HOSP & INST L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in LOTUS EYE HOSP & INST L stood at 93.5% of traded volume, against a 20-day average of 76.6%.
LOTUS EYE HOSP & INST L announcements: results, concalls, ratings, M&A.
Filings LOTUS EYE HOSP & INST L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
LOTUS EYE HOSP & INST L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 51 documents below.
Copy of Newspaper Publication
LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about Copy of Newspaper Publication regarding 29th Annual General…
Shareholders meeting
LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about 29th Annual General Meeting scheduled to be held on September 23,…
Press Release
LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange regarding a press release dated August 27, 2026, titled "Launch of…
Copy of Newspaper Publication
LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about Copy of Newspaper Advertisements published for Standalone…
Outcome of Board Meeting
LOTUSEYE: Lotus Eye Hospital and Institute Limited has submitted to the Exchange, the Standalone Unaudited Financial Results for the period ended…
LOTUS EYE HOSP & INST L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue LOTUS EYE HOSP & INST L has declared, sequenced by announce and record date.
LOTUS EYE HOSP & INST L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About LOTUS EYE HOSP & INST L: business, sector, key facts.
What LOTUS EYE HOSP & INST L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
LOTUS EYE HOSP & INST L operates in the Hospital industry under the Healthcare sector, listed as NSE: LOTUSEYE, BSE: 532998.
Lotus Eye Hospital and Institute Limited is a prominent specialty eye care hospital in India, established in 1989 and headquartered in Coimbatore. The hospital offers a comprehensive range of ophthalmic services, catering to diverse patient needs and encompassing various subspecialties.
Their surgical services are extensive, including a wide array of refractive procedures such as ReLEx SMILE lasik, LASIK eye surgery, epilasik, and Intralase, alongside advanced cataract surgery techniques like robotic femto laser cataract surgery, phacoemulsification, micro incision cataract surgery (MICS), and small incision cataract surgery (SICS). They also perform a variety of corneal surgeries, including penetrating keratoplasty (PKP), deep anterior lamellar keratoplasty (DALK), and corneal patch grafts, as well as glaucoma surgeries like trabeculectomy and other procedures addressing conditions like pterygium and retinal detachments. The hospital also provides specialized pediatric eye care and squint surgery.
Beyond surgical interventions, Lotus Eye Hospital offers a full spectrum of medical treatments. This includes injections for various retinal diseases (like Avastin, Lucentis, and Eylea), management of conditions such as keratoconus, glaucoma, diabetic retinopathy, uveitis, and neuro-ophthalmological disorders. They also address common issues like computer vision syndrome and binocular vision problems.
The hospital's commitment extends beyond direct patient care. It operates an in-house eye bank, optical showroom, and pharmacy, providing patients with convenient access to essential resources. Furthermore, its commitment to education and research is evident through its operation of a research trust, offering a Bachelor of Science degree in optometry, various optical fellowship courses, and a DNB program, contributing to the advancement of ophthalmic care in India.
In summary, Lotus Eye Hospital and Institute Limited provides a holistic approach to eye care, integrating advanced surgical techniques, comprehensive medical treatments, supportive ancillary services, and educational initiatives to establish itself as a leading provider of ophthalmic services in India.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- DR AGARWALS HEALTH CARE L (AGARWALEYE) Share PricePeer
- APOLLO HOSPITALS ENTER L (APOLLOHOSP) Share PricePeer
- ARTEMIS MED SERVICE (ARTEMISMED) Share PricePeer
- ASTER DM QUALITY CARE (ASTERDM) Share PricePeer
- FORTIS HEALTHCARE (FORTIS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about LOTUS EYE HOSP & INST L (LOTUSEYE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of LOTUS EYE HOSP & INST L (LOTUSEYE)?
The current share price of LOTUS EYE HOSP & INST L (LOTUSEYE) is ₹115.10. Today, the stock has gained by ₹1.98 (1.75%), trading in a range of ₹113.00 to ₹115.20. The stock opened at ₹113.12 with a trading volume of 7,112 shares.
02Is LOTUS EYE HOSP & INST L stock a good investment for long-term?
LOTUS EYE HOSP & INST L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹234.27 Cr., P/E ratio of 2,955, ROE of 0.13%, and ROCE of 1.15%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of LOTUS EYE HOSP & INST L stock?
The 52-week high price of LOTUS EYE HOSP & INST L (LOTUSEYE) is ₹147.00, while the 52-week low is ₹97.59. Currently trading at ₹115.10, the stock is 17.94% above its 52-week low and 21.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy LOTUS EYE HOSP & INST L stock at the current price?
Whether to buy LOTUS EYE HOSP & INST L stock at ₹115.10 depends on multiple factors. The stock is currently trading with a P/E ratio of 2,955 and P/B ratio of 4.09. Today's performance shows a gain of 1.75%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of LOTUS EYE HOSP & INST L and when is the next dividend?
LOTUS EYE HOSP & INST L offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹115.10, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of LOTUS EYE HOSP & INST L?
LOTUS EYE HOSP & INST L's key financial metrics include: P/E Ratio: 2,955, P/B Ratio: 4.09, ROE: 0.13%, ROCE: 1.15%, Dividend Yield: 0%, EPS: ₹0.30, Book Value: ₹28.92, and Debt-to-Equity: 0.19. The company's market cap stands at ₹234.27 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is LOTUS EYE HOSP & INST L stock performing today in the market?
LOTUS EYE HOSP & INST L stock opened at ₹113.12 and is currently trading at ₹115.10, showing a gain of ₹1.98 (1.75%). The intraday high is ₹115.20 and low is ₹113.00. The trading volume stands at 7,112 shares, indicating moderate market participation today.
08What is the P/E ratio of LOTUS EYE HOSP & INST L and what does it indicate?
LOTUS EYE HOSP & INST L has a Price-to-Earnings (P/E) ratio of 2,955, which means investors are willing to pay 2,955.00 for every ₹1 of earnings. With an EPS of ₹0.30, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about LOTUS EYE HOSP & INST L (LOTUSEYE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.